ZTS – Market expectations are for Uniform ROA expansion, but management has concerns about markets, growth, and Apoquel

July 2, 2019

  • Zoetis Inc. (ZTS:USA) currently trades at historical highs relative to UAFRS-based (Uniform) Earnings, with a 34.4x Uniform P/E, implying bullish expectations for the firm. However, management has concerns about livestock markets, their portfolio growth, and the potential of the Apoquel launch
  • Specifically, management may be concerned about cattle and swine markets, the launch of Apoquel in China, and their ability to grow due to the future emergence of diseases. Also, they may lack confidence in their ability to sustain growth in Brazilian and Chinese markets, their dermatology portfolio, and Simparica revenue. Furthermore, they may be concerned about young animal product testing, lead generation in the diagnostics market, and the promotion of their dermatology portfolio. In addition, they may be exaggerating the strength of their portfolio, positive market dynamics, and the potential global market for Apoquel.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683